公开(公告)号：US20090076171A1

公开(公告)日：2009-03-19

申请号：US11992249

申请日：2006-09-15

申请人： Yuliang Zhao ,  Chunying Chen ,  Gengmei Xing

发明人： Yuliang Zhao ,  Chunying Chen ,  Gengmei Xing

IPC分类号： A61K31/045 ,  C07C31/28

CPC分类号： A61K33/24 ,  A61K31/28 ,  Y10S977/736 ,  Y10S977/915

摘要： This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C2m(OH)x, wherein M is selected from rare earth elements such as La or Gd; m is carbon atoms of 41 or 30; x is a number of hydroxyl group of from 10 to about 50. Actually, due to the reset of the neighboring hydroxyl, the numbers of O and H in Carbon cage are different, formula are thus written as M@C2mOxHy. Comparing to the clinical anticancer drugs such as Paclitaxel, Cyclophosphamide, and Cisplatin, metallofullerol of M@C2m(OH)x or M@C2mOxHy has superior advantages of higher antitumor efficiency, low dosage, low toxicity, and better biocompatibility.

摘要翻译： 本发明提供多羟基化金属富勒烯化合物的组合物及其在制备抗肿瘤药物中的应用。 在一个实施方案中，包含式M 2 C 2m（OH）x的金属富勒烯，其中M选自稀土元素如La或Gd; m为41或30的碳原子; x是10〜50左右的羟基数。实际上，由于相邻羟基的复位，碳笼中O和H的数目不同，所以公式被写为M @ C2mOxHy。 与紫杉醇，环磷酰胺和顺铂等临床抗癌药物相比，M @ C2m（OH）x或M @ C2mOxHy的金属富勒醇具有较高的抗肿瘤效率，低剂量，低毒性，更好的生物相容性等优点。

公开(公告)号：US08124657B2

公开(公告)日：2012-02-28

申请号：US11992249

申请日：2006-09-15

申请人： Yuliang Zhao ,  Chunying Chen ,  Gengmei Xing

发明人： Yuliang Zhao ,  Chunying Chen ,  Gengmei Xing

IPC分类号： A61K31/047 ,  C07C35/00

CPC分类号： A61K33/24 ,  A61K31/28 ,  Y10S977/736 ,  Y10S977/915

摘要： This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C2m(OH)x, wherein M is selected from rare earth elements such as La or Gd; m is carbon atoms of 41 or 30; x is a number of hydroxyl group of from 10 to about 50. Actually, due to the reset of the neighboring hydroxyl, the numbers of O and H in Carbon cage are different, formula are thus written as M@C2mOxHy. Comparing to the clinical anticancer drugs such as Paclitaxel, Cyclophosphamide, and Cisplatin, metallofullerol of M@C2m(OH)x or M@C2mOxHy has superior advantages of higher antitumor efficiency, low dosage, low toxicity, and better biocompatibility.

摘要翻译： 本发明提供多羟基化金属富勒烯化合物的组合物及其在制备抗肿瘤药物中的应用。 在一个实施方案中，包含式M 2 C 2m（OH）x的金属富勒烯，其中M选自稀土元素如La或Gd; m为41或30的碳原子; x是10〜50左右的羟基数。实际上，由于相邻羟基的复位，碳笼中O和H的数目不同，所以公式被写为M @ C2mOxHy。 与紫杉醇，环磷酰胺和顺铂等临床抗癌药物相比，M @ C2m（OH）x或M @ C2mOxHy的金属富勒醇具有较高的抗肿瘤效率，低剂量，低毒性，更好的生物相容性等优点。

公开(公告)号：USD957838S1

公开(公告)日：2022-07-19

申请号：US29801606

申请日：2021-07-29

申请人： Chunying Chen

设计人： Chunying Chen

公开(公告)号：USD995176S1

公开(公告)日：2023-08-15

申请号：US35515575

申请日：2022-10-28

申请人： Chunying Chen

设计人： Chunying Chen

摘要： 1. Chair base
1.1 : Perspective
1.2 : Perspective
1.3 : Front
1.4 : Back
1.5 : Left
1.6 : Right
1.7 : Top
1.8 : Bottom
1.9 : Enlarged
1.10 : Folded state reference
1.11 : Folded state reference
The parts shown by means of broken lines in the reproductions are not part of the claimed design; fig. 1.9 is an enlarged view of a portion labeled “9” in fig. 1.1; the dash-dot-dash lines in fig. 1.1 and fig. 1.9, and the label “9” in fig. 1.1 are for the purpose of depicting the cut line of the enlarged view and form no part of the claimed design.

公开(公告)号：US11684161B1

公开(公告)日：2023-06-27

申请号：US17988200

申请日：2022-11-16

申请人： Chunying Chen

发明人： Chunying Chen

IPC分类号： A47C1/16

CPC分类号： A47C1/16

摘要： The portable bleacher chair provided by the present disclosure includes a base and a backrest rotatably connected to amend of the base. The base includes a pair of main rods arranged in parallel and a foldable assembly connected between the pair of main rods. The foldable assembly is configured to be in a folded state or an unfolded state, and a distance between the pair of main rods varies with a transition between the folded state and the unfolded state of the foldable assembly. Since the base includes the foldable assembly, the portable bleacher chair provided by the present disclosure is small, compact, and easy to carry in the folded state.